An analysis of a lung adenocarcinoma retrospective cohort (n = 72) from the BATTLE2 clinical trial (ClinicalTrials.gov ID: NCT01248247) revealed that MTAP deficiency correlates with a heightened response rate to pemetrexed. This evidence concerns the gene MTAP and lung adenocarcinoma.